Chuck Riggs, M.D.

Chuck Riggs, M.D.

(352) 265-0725

Current patients:
Log in to MyUFHealth

Publications

Racial disparity in oral and pharyngeal cancer in Florida in 1991-2008: mixed trends in stage of diagnosis.
Community dentistry and oral epidemiology
2013

Selecting a comparison group for 5-year oral and pharyngeal cancer survivors: two methods.
BMC medical research methodology
2012

Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.
Cancer
2010

Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma.
Head & neck
2010

Squamous Cell Carcinoma of the Anal Margin: the Uf Experience
International Journal of Radiation Oncology Biology Physics
2009

Definitive altered fractionation radiotherapy and concomitant weekly cisplatin for locally advanced head and neck cancer.
American journal of clinical oncology
2009

Cisplatin 30 Mg/M(2)/Week Decreases Toxicity Without Sacrificing Efficacy in Patients Treated With Concomitant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
International Journal of Radiation Oncology Biology Physics
2009

Sinonasal undifferentiated carcinoma.
American journal of clinical oncology
2006

Adult head and neck soft tissue sarcomas.
Head & neck
2005

Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck.
The Laryngoscope
2003

Research Interests

Dr. Riggs participates in multidisciplinary treatment programs in head and neck cancer, lung cancer, esophageal cancer, thyroid cancer, and sarcomas of soft tissue and bone, in both the UF/Shands and VA medical systems. He is a member of the UF/Shands Cancer Center, and serves the University as Vice-Chair of the medical IRB, with expertise in oncology clinical trials, biomedical ethics, and pharmacoeconomics. He teaches biomedical ethics to medical students, and participates in teaching physical diagnosis to medical students and oncology topics to trainees in the residency and fellowship programs.

Multidisciplinary collaborative trials in head and neck cancer constitute the primary focus of Dr. Riggs' current research efforts. He participates in local and national investigational trials in sarcomas and prostate cancer, as well. Integration of targeted therapies into traditional combined-modality treatment programs for head and neck and thyroid cancers are proceeding through University of Florida clinical trials, and expansion of these approaches into esophageal cancer and sarcoma chemotherapy trials is anticipated.